ERCC8

Across TCGA pan-cancer cohorts, ERCC8 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ERCC8 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ERCC8 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ERCC8 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where ERCC8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.859	0.974	<.001	63	view →
PDAC	DFS	Quartile	All	0.958	0.396	.007	17	view →
HNSC	DFS	Median	II,III,IV	0.989	0.861	.002	16	view →
CCRCC	OS	Tertile	All	0.942	0.806	.023	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ERCC8–LUAD (DFS)

Open the LUAD breakdown →